Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers

A Yaghoubi, S Asli, M Parhizkar… - Iranian Journal of …, 2023 - iji.sums.ac.ir
Background: Measuring the level of antibodies produced post-vaccination in response to the
SARS-CoV-2 spike protein is considered a strategy for estimating the effectiveness of the …

[HTML][HTML] RBD targeted COVID vaccine and full length spike-protein vaccine (mutation and glycosylation role) relationship with procoagulant effect

M Luisetto, G Tarro, FA Khan… - Journal of Child …, 2021 - vaccinesimmunojournal.com
| JCAVI | HSPI HSPI About AZ Journals All Articles eBooks Publish with Us Contact History (0)
Covid-19 Articles Journals Journals Global Home About Editorial Board Browse Articles …

Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

DG Bermudes - US Patent 11,406,702, 2022 - Google Patents
9/1997 Curtiss, III 10/1997 Pace et al. 10/1997 Curtiss, III et al. 11/1997 Curtiss, III et al.
12/1997 Miller et al. 2/1998 Raff 3/1998 Miller, III et al. 4/1998 Haun et al. 5/1998 …

Development of immunogenic, distributable, and equitable SARS-CoV-2 vaccines

MS Khan - 2023 - search.proquest.com
The COVID-19 pandemic underscores the critical need for effective vaccines against SARS-
CoV-2. This thesis investigates diverse aspects of SARS-CoV-2 vaccine development …

DEVELOPMENT OF A NOVEL SUB-UNIT CANDIDATE VACCINE FOR MERS-COV

MY Khan - 2023 - platform.almanhal.com
Coronaviruses belong to the coronaviridae family that comprises species of longest known
positive sense single-strand Ribo Nucleic Acid (ssRNA) genome (25-32Kbps) and a …

[PDF][PDF] Application of Secreted Bacterial Outer Membrane Vesicles (OMVs) to Develop A Candidate Vaccine for Middle East Respiratory Syndrome Coronavirus …

TA Bouback, I Qadri, F Al-fassi, MA Ali - Middle-East J. Sci. Res, 2019 - aensiweb.net
Background and Objective: A novel coronavirus Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) emerged in 2012 in Saudi Arabia and caused high mortality rates …

Application of nanotechnology in drug development and delivery for SARS-CoV-2 treatment

R Karunakaran, SP Sadanandan - Coronavirus Drug Discovery, 2022 - Elsevier
The world is currently witnessing the COVID-19 pandemic, a disease caused by a novel
coronavirus, severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Currently …

[PDF][PDF] In-silico vaccine design against novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV2) using immunoinformatics approach

JD Barua, N Das, NA Munia, S Raju - Journal of Pharmaceutical …, 2021 - researchgate.net
The novel Coronavirus, also known as Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) is a contagion for the coronavirus disease commonly known as COVID-19 …

Fluorescent probe based biosensor and assay for the detection of SARS-CoV-2

HA Alhadrami, M Zourob - US Patent 10,962,529, 2021 - Google Patents
A method for detecting a SARS-Cov-2 protease in bio logical sample is provided. The
method includes contacting the biological sample with a fluorescent probe based sensor …

Vaccine Development and Immune Responses in COVID-19: Lessons from the Past

F Fatemi, Z Hassani Nejad, SER Siadat - COVID-19: Science to Social …, 2021 - Springer
Abstract The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently one of the biggest threats to …